Italia markets close in 1 hour 9 minutes
  • Insider Monkey

    Vicor Corporation (NASDAQ:VICR) Q1 2024 Earnings Call Transcript

    Vicor Corporation (NASDAQ:VICR) Q1 2024 Earnings Call Transcript April 23, 2024 Vicor Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone and thank you for standing by. Welcome to the Q1 2024 Vicor Earnings Conference Call. [Operator […]

  • GlobeNewswire

    Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114

  • GlobeNewswire

    Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-